{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:04:07Z","timestamp":1771427047406,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pharma.2025.10.004","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:30:28Z","timestamp":1760099428000},"page":"240-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of thromboembolic events after recombinant coagulation factor VIIa (rFVIIa - NovoSeven\u00ae) use in cardiac surgery: A descriptive pilot study"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7057-6592","authenticated-orcid":false,"given":"Delphine","family":"Boden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Bouchand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Fenat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Leichnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles-Henri","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Rigal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Bonsergent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2025.10.004_bib0095","unstructured":"Leo-Kodeli S, Forest V, Leclerc M. H\u00e9morragie massive\u00a0: harmonisation des pratiques transfusionnelles. https:\/\/hemovigilance-cncrh.fr\/wp18\/wp-content\/uploads\/2018\/06\/DIAPO-DR-LEO-KODELI-HEMORRAGIES-MASSIVES.pdf. Accessed 02 Feb 2023."},{"issue":"2","key":"10.1016\/j.pharma.2025.10.004_bib0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.annfar.2006.10.008","article-title":"Recommandations europ\u00e9ennes pour l\u2019utilisation du facteur VII activ\u00e9 recombinant comme th\u00e9rapeutique adjuvante du saignement majeur","volume":"26","author":"Vincent","year":"2007","journal-title":"Ann Fr Anesth Reanim"},{"issue":"4","key":"10.1016\/j.pharma.2025.10.004_bib0105","first-page":"485","article-title":"Systemic venous thrombosis after recombinant factor viia in the control of bleeding after cardiac surgery","volume":"34","author":"Mahmoud","year":"2007","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.pharma.2025.10.004_bib0110","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics NovoSeven\u2013INN-eptacog alfa (activated). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/novoseven-epar-product-information_en.pdf. Accessed 16 Dec 2022."},{"issue":"1","key":"10.1016\/j.pharma.2025.10.004_bib0115","first-page":"62","article-title":"Recommandations sur la r\u00e9animation du choc h\u00e9morragique","volume":"1","author":"Duranteau","year":"2015","journal-title":"Anesth Reanim"},{"issue":"10","key":"10.1016\/j.pharma.2025.10.004_bib0120","first-page":"809","article-title":"Safety and efficiency of recombinant activated factor VII in postcardiotomy massive hemorrhage","volume":"23","author":"Lamarche","year":"2007","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.pharma.2025.10.004_bib0125","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/ejcts\/ezs043","article-title":"EuroSCORE II","volume":"41","author":"Nashef","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"issue":"6","key":"10.1016\/j.pharma.2025.10.004_bib0130","first-page":"1320","article-title":"Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23\u00a0French cardiac centres (2005-7)","volume":"40","author":"Hacquard","year":"2011","journal-title":"Eur J Cardio-Thorac Surg"},{"issue":"1","key":"10.1016\/j.pharma.2025.10.004_bib0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.jvca.2008.08.003","article-title":"Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes","volume":"23","author":"Masud","year":"2009","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"7","key":"10.1016\/j.pharma.2025.10.004_bib0140","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MBC.0000000000001079","article-title":"Very low-dose recombinant Factor VIIa administration for cardiac surgical bleeding reduces red blood cell transfusions and renal risk: a matched cohort study","volume":"32","author":"Cotter","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"11","key":"10.1016\/j.pharma.2025.10.004_bib0145","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1053\/j.jvca.2019.04.003","article-title":"Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for management of perioperative bleeding and hemostasis in cardiac surgery patients","volume":"33","author":"Raphael","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"9","key":"10.1016\/j.pharma.2025.10.004_bib0150","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/j.1537-2995.2004.04052.x","article-title":"Transfusion medicine service policies for recombinant factor VIIa administration","volume":"44","author":"Goodnough","year":"2004","journal-title":"Transfusion (Paris)"},{"issue":"8","key":"10.1016\/j.pharma.2025.10.004_bib0180","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.healun.2009.04.028","article-title":"High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII","volume":"28","author":"Bruckner","year":"2009","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.pharma.2025.10.004_bib0155","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.CCM.0000159087.85970.38","article-title":"Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review","volume":"33","author":"Levi","year":"2005","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.pharma.2025.10.004_bib0160","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.athoracsur.2006.10.033","article-title":"Recombinant activated factor VII in cardiac surgery: a systematic review","volume":"83","author":"Warren","year":"2007","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1016\/j.pharma.2025.10.004_bib0165","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1053\/j.jvca.2021.03.021","article-title":"Efficacy, safety, and strategies for recombinant-activated factor VII in cardiac surgical bleeding: a narrative review","volume":"36","author":"Kidd","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"3","key":"10.1016\/j.pharma.2025.10.004_bib0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","article-title":"Thromboembolic adverse events after use of recombinant human coagulation factor VIIa","volume":"295","author":"O\u2019Connell","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharma.2025.10.004_bib0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1537-2995.2005.04216.x","article-title":"Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis","volume":"45","author":"Karkouti","year":"2005","journal-title":"Transfusion (Paris)"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345092500149X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345092500149X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:05:55Z","timestamp":1771423555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000345092500149X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S000345092500149X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2025.10.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of thromboembolic events after recombinant coagulation factor VIIa (rFVIIa - NovoSeven\u00ae) use in cardiac surgery: A descriptive pilot study","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}